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Abstract : The anti-human epidermal growth factor receptor 2 ?HER2? antibody 
?Ab? is a molecularly targeted Ab for cancer therapy.  In the eld of breast can-
cer, approximately 20? overexpress HER2 protein.  However, the recurrence rate 
is 30? and the metastasis rate is 18? one year after treatment of anti-HER2 Ab 
for HER2 positive breast cancer.  The resistance to Ab treatment is a major prob-
lem for patients.  We previously reported that anti-HER2 Ab and Gamma Interfer-
on ?IFN-?? combined therapy show a higher anti-tumor effect than typical therapy 
in in vitro and in vivo mouse experiments.  In this study, we evaluated whether 
anti-HER2 Ab and IFN-? combined therapy shows a good synergistic effect 
against drug-resistant HER2 positive breast cancer cells and a higher antitumor 
effect than chemotherapy as a conventional clinical treatment.  Further, we evalu-
ated a synergy effect with the PD-L1 as a new check point inhibitor.  The resistant 
cell lines were made under the continuous presence of Ab until cell growth was 
not affected by the drug.  The resistant cells were divided into the appropriate 
number of groups, and then treated with anti-cancer therapy.  We evaluated the 
antitumor effect for both the in vitro study and in vivo mouse xenograft model 
prepared with the same immunogenicity.  The differences of immunouorescence 
staining of CD8, Gr-1 and PDL-1 in tissues were investigated, especially in relation 
to the immune system.  The combined therapy showed a signicantly higher anti-
tumor effect than other groups in in vitro and in vivo experiments.  The combined 
therapy affected anti-tumor immunity in this immunofluorescence experiment.  
Taken together, we showed the possibility that combined therapy could be an 
effective treatment option for anti-HER2 Ab resistant breast cancer, thus helping 
patients suffering from cancer progression after developing treatment resistance.
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Introduction
?Human epidermal growth factor receptor 2 ?HER2? belongs to the HER family of receptors 
with tyrosine kinase activity.  HER2 affects cell proliferation, cell differentiation, apoptosis, and 
cell survival through signal transduction systems such as PI3K, MAPK, RAS, and SRC 1?.  The 
overexpression of HER2 is associated with carcinogenesis 2?3?, with overexpression and genetic 
amplification of HER2 found in many cancer types including 20-30? of breast cancers, 
10-20? of stomach cancers, and others ?uterine, head and neck, and esophageal cancers?.  The 
expression level of HER2 correlates with the malignancy of the cancer and is associated with a 
poor prognosis 3?4?.
?Trastuzumab is a monoclonal anti-HER2 Ab used to treat breast and gastric cancer via 
attachment of the ectodomain of HER2.   The treatment outcome for HER2-positive cancer has 
improved since the appearance of Trastuzumab 5?.
?Herceptin? with chemotherapy is currently recommended as the primary therapy for HER2-
positive breast cancer and gastric cancer 6?7?.  Trastuzumab? Pertuzumab? chemotherapy is a 
standard therapy for HER2-positive unresectable breast cancer and distant metastasis breast cancer, 
and Herceptin? capecitabine or 5-fluorouracil plus cisplatin is the standard therapy for HER2-
positive gastric cancer, extending median overall survival : 13.8 months vs.  11.1 months ; hazard 
ratio ?HR? 0.74 ; 95? confidence interval ?CI?, 0.60-0.91 ; P? 0.0046, vs chemotherapy alone5?.
?Despite these advances, cancer cells still develop resistance to medical treatment.  In fact, 
nearly all HER2-positive metastatic patients eventually succumb to their disease, and while the 
5-year survival rate of progressive and recurrent breast cancer is 5-10?, the overall survival rate 
of HER2-positive gastric cancer treated with Herceptin?? chemotherapy is only 13.8 months 5?8?. 
At present, few studies on cancers that develop resistance to anti-HER2 Ab therapy have been 
conducted, thus the next best alternative therapy remains to be established 8?9?.
?Cancer immunotherapy has attracted attention in recent years.  In fact, cancer immunotherapy 
was chosen as the ?breakthrough of the year? in 2013 in the journal Science.  Checkpoint 
inhibitors, including nivolumab and ipilimumab, have already shown some promising results for 
unresectable cancers 10?11?.  New cancer immunological therapies are therefore anticipated for the 
treatment of unresectable and metastatic cancer that is resistant to conventional therapy, with 
encouraging results from a variety of ongoing clinical trials 12?13?.  In this study, we therefore 
evaluated and investigated the anti-tumor effect of anti-HER2 Ab? IFN-?? PD-L1 treatment.  
?Previously, we showed that there was a very high antitumor effect for combination therapy 
of monoclonal Ab and IFN-? using an experiment system that fixed the same immunogenicity 
for mouse, cancer cell line, and the Ab.  In that work, the Ab and IFN-? combined therapy 
? acted in cancer cells to change the malignancy itself, ? changed the signal transduction, 
? affected the cell cycle and inhibited cell proliferation, ? accelerated CD8T cell cytotoxicity, 
and ? decreased the number of Myeloid Derived Suppressor Cells ?MDSCs? that inhibit the 
antitumor effect and raise immunoreactivity within the tumor tissue14?.
  Therefore, we hypothesized that the anti-HER2 Ab and IFN-? combined therapy might be 
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useful for cancers that developed resistance to anti-HER2 Ab.  Thus, the present study evaluated 
whether Trastuzumab and IFN-? combined therapy could act synergistically against drug-resistant 
HER2-positive human breast cancer cells.
Materials and methods
Cell lines and culture condition
?H2N113
?The H2N113 tumor cell line was generated from female Balb/c MMTV-ErbB-2 / neu transgenic 
mice with spontaneous breast cancer.  The H2N113 cell lines were cultured in RPMI-1640 
medium containing L-Glutamine ?5 ml / 500 ml? ?Gibco Life Technologies, Carlsbad, CA, USA?, 
supplemented with 10? fetal bovine serum ?Biosera, Kansas City, MO, USA?, sodium pyruvate 
?5 ml / 500 ml? ?Gibco Life Technologies?, Glutamax ?5 ml / 500 ml? ?Gibco Life Technologies?, 
MEM NEAA ?5 ml / 500 ml? ?Gibco Life Technologies?, Gibco penicillin-streptomycin liquid 
?5,000 units/ml penicillin / 5,000 µg/ml streptomycin? ?Gibco Life Technologies? at 37ºC with 5? 
carbon dioxide in 95? air.
?H2N113R
?We developed the resistant cancer cell line treatment by a widely published method.  Briefly, 
the resistant cell line ?H2N113R? was made under the continuous presence of 7.16.4 Ab, and 1
? 105 H2N113 cells were seeded on 10-cm petri dishes ; 7.16.4 Ab was added every 3 days as 
the cells were passaged until confluent.  The concentration of 7.16.4 Ab was gradually increased 
from 2 µg/ml to 20 µg/ml, 40 µg/ml, 60 µg/ml, 80 µg/ml, and 100 µg/ml finally.  
?Drugs
?The 7.16.4 was used as the anti-mouse ErbB2 monoclonal Ab and was purified from a clone 
7.16.4 hybridoma kindly provided by Mark Greene ?John W. Eckman Professor of Medical 
Science, University of Pennsylvania Perelman School of Medicine, Director, Immunobiology and 
Experimental Pathology Division?.
?Mouse IFN-? was purchased from PROSPEC ?PROSPEC Protein Specialists, Rohovot, Israel?. 
Docetaxel ?DTX? was purchased from LC Laboratories ?LC Laboratories, Woburn, MA, USA? 
and diluted with dimethyl sulfoxide ?DMSO?.  Anti-mouse PD-L1 Ab was purchased from 
BioXcell ?mouse PD-L1 ?B7-H1?, BE0101, inVivoMab, Lebanon, NH, USA?.  For the Ab and 
IFN-? combined treatment, IFN-? was added 30 minutes after Ab treatment in all experiments.
Cell Growth in vitro Proliferation Assay
?We set up three groups as follows : control group, 7.16.4 group, and 7.16.4? IFN-? group.  We 
seeded 1?10 5 H2N113R cells onto three 6-well plates containing normal culture media and these 
were divided equally into the three groups described above.  Drug treatments were initiated 
after eight hours from seeding the cells.  The cell culture was analyzed at two separate times ?3 
and 7 days?, the cell number was recorded, and the cell growth curve was developed.  Nothing 
was added to the control group.  The 7.16.4 group was treated with 10 µg/ml of 7.16.4 Ab and 
the 7.16.4? IFN-? group was treated with 10 µg/ml of 7.16.4 Ab and 100 IU/ml of IFN-?.  Cell 
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number was counted by automated cell counting ?Bio-Rad Laboratories, In c., Hercules, CA.?.  
Mouse in vivo Experiment 
?Eight-week-old female Balb/c mice were bought and bred for one week to adjust the 
environment for this experiment.  Then 1?106 H2N113R cells were injected subcutaneously into 
both sides of the back of the mice.  We distributed the mice into 4 groups to adjust the tumor 
size among the four groups and started drug treatment at 14 days after tumor inoculation.
?We treated the groups as follows : control with PBS 100 µl ?n? 9?, 7.16.4 Ab 100 µg / 100 µl 
PBS to the 7.16.4 group ?n? 11?, IFN-? 10,000 IU / 100 µl PBS to the IFN-? group ?n?
8?, and 7.16.4 Ab 100 µg / 100 µl PBS and IFN-? 10,000 IU / 100 µl PBS to the 7.16.4 ? IFN-
? combined therapy group ?n? 11?.  Drugs were delivered by intraperitoneal injection.  In the 
combined therapy group, IFN-? was added 30 minutes after the 7.16.4 injection.  The drugs were 
given three times a week.  Tumor size was measured three times a week with a digital caliper 
carbon fiber and calculated using a simple algorithm ?length ? width ? height?.  
Mouse in vivo Comparative Experiment in Clinical use
?We did the same in vivo experiment using H2N113R cells, dividing the cells this time into 
6 groups as follows : administered PBS 100 µl to the control group ?n? 5?, 7.16.4 Ab 100 µg / 
100 µl PBS to the 7.16.4 group ?n? 8?, DTX 100 µg / 100 µl DMSO to the DTX group ?n?
7?, 7.16.4 Ab 100 µg / 100 µl PBS and IFN-? 10,000 IU / 100 µl PBS and DTX 100 µg / 100 µl 
DMSO to the 7.16.4? IFN-??DTX combined therapy group ?n? 10?, anti-PD-L1 Ab.
?100 µg / 100 µl PBS to the aPD-L1 group ?n? 7?, and 7.16.4 100 µg / 100 µl PBS and IFN-? 
10,000 IU / 100 µl PBS and aPD-L1 Ab 100 µg / 100 µl PBS to the 7.16.4? IFN-?? aPD-L1 
combined therapy group ?n? 9?.  Drugs were delivered by intraperitoneal injection.  In the 
combined therapy group, IFN-? was added 30 minutes after 7.16.4 injections.  Docetaxel and 
aPD-L1 were given three times a week.  Tumor size was measured three times a week with a 
digital caliper carbon fiber ?19978, Sink, Niigata, Japan? and calculated using a simple algorithm 
?length ? width ? height?.  Tumors were removed from the mice on day 21 of the drug 
treatment.  Specimens were fixed in 10? formaldehyde for 24 hours.
Fluorescent Immunohistochemistry 
?Tumors were removed from the mice on day 16 of the drug treatment for the in vivo 
experiments and from the mice on day 21 of the drug treatment for the in vivo experiments 
with chemotherapy.  Specimens were fixed in 10? formaldehyde for 24 hours.  
?Tumor specimens were cut at a thickness of 3 µm and fixed in 10? formaldehyde.  Sections 
were stained by hematoxylin and eosin ?H & E?.  Immunostaining was performed by incubating 
these sections again in 0.3? H2O2 for 5 minutes to remove endogenous peroxidase activity and 
then in the Dako nonspecific blocking reagent for 5 minutes.  The sections were then incubated 
with a CD8 ?1?100? ?LEAF TMPurified anti-mouse CD8a, 100715, BioLegend?, San Diego, CA, 
USA?, Gr-1 ?1?100? ?Purified anti-mouse Ly-6G / Ly-6c, 108401, BioLegend??, PDL-1 ?1?1,000? 
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?mouse PDL-1 ?B7-H1?, or BE0101, inVivoMab? for 1 hour at room temperature, followed by 
a secondary, TRITC-conjugated anti-rabbit IgG ?A21428, Life Technologies? and bisbenzimide 
H33342 ?DojinDO Molecular Technologies, Inc., Kumamoto, Japan? in a humid chamber at 37?C 
for 30 min.  The images were captured on a BZ-X800 fluorescent microscope ?Keyence, Osaka, 
Japan? and were quantitated with Hybrid Cell Count BZ-H4C software ?Keyence?.
Statistical analysis
?Statistical analysis was carried out using YSAT 2013 ?Igakutosho-shuppan Ltd., Toda, Japan?. 
Differences in mean values were statistically analyzed using the non-parametric repeated 
measures Friedman?s test followed by the Wilcoxon test in vitro study.  Non-repeated measures 
ANOVA followed by Dunnett?s test was done for the in vivo studies.  A P-value under 0.05 
was used to determine statistically significant differences in all experiments.  We set the 7.16.4?
IFN-? levels as a statistical control to analyze in Figures 1, 2, 5, 6, 7 and 7.16.4? IFN-?? PD-L1 
in Figures 3, 9, 10, 11.
Results
Combined 7.16.4 ? IFN-? therapy suppressed the H2N113R Cell Growth in an in vitro 
proliferation assay
?The average cell numbers on day 3 and day 7 were 4.40 ? 10 5 and 68.1 ? 10 5 cells, respectively, 
in the control group, 3.8 ? 10 5 and 62.6 ? 10 5 cells, respectively, in the 7.16.4 group, and 3.04 ?
10 5 and 51.6 ? 10 5 cells, respectively, in the 7.16.4? IFN-? group.
Fig.?1.??7.16.4? IFN-? therapy suppressed H2N113R cell growth in vitro
H2N113R cells ?1? 10 5? were seeded onto 6-well plates for the in vitro proliferation assay : Control, 
7.16.4 ?10 µg/ml?, 7.16.4? IFN-? ?10 µg/ml? 100 IU/ml?. Treatment was started after 8 hours from 
seeding and continued during 7 days of culture. The cell numbers were counted on days 3 and 7 to 
construct a cell growth curve. Cell number was established using an automated cell counter ?Bio-Rad 
Laboratories, Inc., Hercules, CA?.
The 7.16.4? IFN-? combined treatment significantly decreased the cell number compared to the control 
group ?P? 0.05?, whereas the 7.16.4 group alone showed no significant difference to control cells. 
The curves show the mean? standard deviation of the number of cells from three independent culture 
experiments ?Friedman?s test followed by Wilcoxon t-test ?P? 0.05 ; n? 6?. 
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?Thus on day 7, the 7.16.4? IFN-? group cell number was 75.8? of that in the control group, 
compared to 91.9? for the 7.16.4 group, indicating that the 7.16.4? IFN-? combined treatment 
significantly decreased the cell number compared to controls, whereas the 7.16.4 group showed 
no significant difference to controls ?Figure 1?.
?The 7.16.4 Ab did not suppress growth in cell number of the H2N113R line, indicating that 
these cells acquired resistance after continuous presence of the antibody and that we can use 
this cell line as a resistant cell line.  In addition, 7.16.4? IFN-? combined treatment significantly 
decreased the cell number, thus the combined therapy effectively suppresses tumor growth in 
vitro without the effect in immune cells.  
The 7.16.4? IFN-? therapy showed an antitumor effect against resistant H2N113R cells in a mice 
Xenograft model
?We set up an in vivo mice Xenograft experiment to investigate the antitumor effects of 7.16.4? 
IFN-? under the condition of the effective immunity including the effect of Ab-dependent 
cellular cytotoxicity ?ADCC? and complement-dependent cytotoxicity ?CDC?.  We used the 
same immunogenicity condition to investigate the real immunoreaction without immune response 
to invasion by foreign substances.  For example, we used the Balb/c mice, H2N113R cells from 
the Balb/c mice, 7.16.4 that is mouse IgG, mouse IFN-?, and mouse anti-PD-L1 Ab.  The 7.16.4
? IFN-? treatment significantly suppressed tumor volumes compared with the other groups from 
Fig.?2.?? 7.16.4? IFN-? therapy elicited an antitumor effect against resistant H2N113R cells in a 
Xenograft mouse model
H2N113R cells ?1? 10 6? were injected subcutaneously into both sides of the backs of Balb/c mice. 
We started drug treatment at day 14 post-injection ?day 0 in the figure? after dividing the mice into 4 
groups : control ?PBS 100 µl?, 7.16.4 ?100 µg / 100 µl PBS?, IFN-? ?10,000 IU / 100 µl PBS?, 7.16.4? IFN-? 
?100 µg / 100 µl PBS? 10,000 IU / 100 µl?. Tumor volumes were calculated as length ?width ? height. 
Measurements and drug treatments were performed three times a week. 
7.16.4? IFN-? treatment significantly suppressed tumor volumes compared with the other groups from 
day 7 until the end ??P? 0.05?. The curve shows the mean? standard deviation of tumor volumes ; the 
numbers of tumors shown as below ?Cont : n? 9, 7.16.4 : n? 11, IFN-?: n? 8, 7.16.4? IFN-?: n?
10?. Non-repeated measures ANOVA followed by Dunnett?s test were done for the in vivo study. We set 
7.16.4? IFN-? as the statistical control.
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day 7 to day 16 ?Figure 2?.  Treatment with 7.16.4 alone showed the tendency for tumor regression, 
but not a significantly suppressed tumor volume compared with the other groups.  On the other 
hand, IFN-? alone showed no anti-tumor effect, but rather, the tumor volume actually increased.
The 7.16.4? IFN-? combined therapy showed potential for future clinical antitumor treatment 
against Ab treatment-resistant tumors
?We did a similar mice Xenograft experiment using six groups this time and used the drugs 
that are clinically used.
?The 7.16.4? IFN-?? aPD-L1 and 7.16.4? IFN-??DTX groups showed significant levels of 
tumor suppression compared with the other groups from day 7 to day 21 ?Figure 3?.  Although 
there was not significant difference between the 7.16.4? IFN-??DTX and aPD-L1 group, the 
7.16.4? IFN-?? aPD-L1 group showed a tendency toward being the most tumor-suppressive 
treatment.  On the other hand, treatment with aPD-L1, DTX and 7.16.4 alone showed no 
significant difference in tumor suppression.  This indicates that 7.16.4? IFN-? therapy is a key 
component in treating Ab-resistant tumors.  
Fig.?3.?? 7.16.4? IFN-? therapy shows potential for clinical antitumor treatment against Ab treatment-
resistant tumors 
Balb/c mice were injected subcutaneously into both sides of the back with 1? 10 6 H2N113R cells. We 
started drug treatment at day 14 post-injection ?day 0 in the figure? after dividing the mice into 6 
groups : control ?PBS 100 µl?, 7.16.4 ?100 µg / 100 µl PBS?, DTX ?DTX 100 µg / 100 µl DMSO?, 7.16.4
? IFN-??DTX ?100 µg / 100 µl 7.16.4 / PBS? 10,000 IU / 100 µl IFN-?/ PBS? 100 µg / 100 µl DTX /
DMSO?, aPD-L1 ?aPD-L1 100 µg / 100 µl PBS?, 7.16.4? IFN-?? aPD-L1 ?100 µg / 100 µl 7.16.4 / PBS?
10,000 IU / 100 µl IFN-?/ PBS? 100 µg / 100 µl aPD-L1 / PBS?. Tumor volumes were calculated as length
?width? height. Measurements and drug treatments were performed three times a week. The curve 
shows the mean? standard deviation of the tumor volumes ; the numbers of tumors were as shown 
below ?Cont : n? 5, 7.16.4 : n? 8, DTX : n? 7, 7.16.4? IFN-??DTX : n? 10, aPD-L1 : n? 7, 7.16.4?
IFN-?? aPD-L1 : n? 9?. Non-repeated measures ANOVA followed by Dunnett?s test were used for the 
in vivo study. We set 7.16.4? IFN-?? PD-L1 as the statistical control.
7.16.4? IFN-?? aPD-L1 treatment showed the most tumor suppression compared with the other groups 
on day 7 and from day 12 to the end significantly ??P? 0.05?.
Treatment with 7.16.4? IFN-??DTX or aPD-L1 significantly suppressed tumor volumes compared with 
the control, aPD-L1, DTX, and 7.16.4 alone treatment ??P? 0.05?. 
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Histopathological examination of mice Xenograft model
?H & E staining was performed to detect differences in histopathological changes in tumor 
tissue among the different treatment groups.  In the 7.16.4? IFN-? group, the tumor was 
characterized by atrophy, vacuolization, and interstitial lymphocyte proliferation, whereas the other 
groups showed a large number of tumors with a swollen appearance ?Figure 4?.
?To investigate the immunity differences among the different treatments tested for resistant 
breast cancer, we ascertained the expression of surface antigen proteins, CD8, Gr-1, and PD-L1 
by immunofluorescence staining.
?Based on fluorescence intensity, the protein expression levels of CD8 in the 7.16.4? IFN-? 
groups were significantly greater than in the other groups ?Figure 5?, while there was 
significantly reduced Gr-1 and PD-L1 expression ?Figures 6, 7?.  There was no significant 
difference in the expression levels of CD8 and Gr-1 among the control, 7.16.4, and IFN-? 
groups.  Compared with the control group, PD-L1 expression was significantly greater in the Ab 
and IFN-? alone groups.
Fig.?4.??Histopathological examination of mice Xenograft model
Hematoxylin/Eosin ?H&E? staining was performed to compare the histopathological changes in tumor 
tissue among the different treatment groups. 
Tumors were removed from the mice on day 16 of the drug treatment in the in vivo experiment, and 
images were captured by fluorescence microscopy ?BZ-X800 ; Keyence, Osaka, Japan?. 
In the 7.16.4? IFN-? group, the tumor showed atrophy, vacuolisation, and interstitial lymphocyte 
proliferation. In the other group, a large number of tumors appeared swollen.
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Fig.?5.??Fluorescence intensity of CD8
The fluorescence intensity of CD8 in Figure 4 was quantified using Hybrid Cell Count BZ-H4C 
software ?Keyence, Osaka, Japan?.
The protein expression levels of CD8 in the 7.16.4? IFN-? groups were significantly greater compared 
to the other groups ??P? 0.05?. Non-repeated measures ANOVA followed by Dunnett?s test. We set 
7.16.4? IFN-? as the statistical control.
Fig.?6.??Fluorescence intensity of Gr-1
The fluorescence intensity of Gr-1 in Figure 4 was quantified as described for Figure 5.
Fig.?7.??Fluorescence intensity of PD-L1
The fluorescence intensity of PD-L1 in Figure 4 was quantified as described for Figure 5.
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Histopathological examination in clinical treatment 
?In the 7.16.4? IFN-??DTX and 7.16.4? IFN-?? aPD-L1 groups, the tumor was 
characterized by atrophy and interstitial lymphocyte proliferation ?Figure 8?.  The 
immunofluorescence staining also showed significantly higher expression of CD8 in the 7.16.4?
Fig.?8.??Histopathological examination of mice Xenograft model using DTX, aPD-L1 
H & E staining and the fluorescence intensity of CD8, Gr-1, and PD-L1 was performed in the clinical 
use mouse model as described for Figure 4.
Fig.?9.??Fluorescence intensity of CD8
The fluorescence intensity of CD8 in Figure 8 was quantified as described for Figure 5.
Non-repeated measures ANOVA followed by Dunnett?s test. We set 7.16.4? IFN-?? PD-L1 as the 
statistical control.
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IFN-?? aPD-L1 group compared to the other groups ?Figure 9?, and significantly lower Gr-1 
expression in the 7.16.4? IFN-?? aPD-L1 and 7.16.4? IFN-??DTX groups ?Figure 10?.  In 
the DTX alone group, PD-L1 expression was significantly lower than that in the control group, 
but significantly higher in the 7.16.4? IFN-?? PD-L1 group ?Figure 11?.  
Discussion
The combined Ab? IFN-? therapy directly acted on cancer cells and inhibited cell proliferation 
against a resistant cancer cell line
?Few studies to date have used the same immunogenicity of mouse, Ab and tumor cell lines. 
In particular, we cannot obtain the Ab resistant tumor cells from humans.  Therefore we cannot 
know which immunological mechanism is taking place in patients.  Thus for this study we made 
a cell line resistant to Ab therapy based on H2N113 cells derived from Balb/c mice to maintain 
Fig.?10.??Fluorescence intensity of Gr-1
The fluorescence intensity of Gr-1 in Figure 8 was quantified as described for Figure 9.
Fig.?11.??Fluorescence intensity of PD-L1
The fluorescence intensity of PD-L1 in Figure 8 was quantified as described for Figure 9.
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consistent immunogenicity.
?The mechanism of drug resistance in cancer cells extends further than the issue of altered 
signal transduction in cells.  It also relates to cells? ability to avoid the immune system.  Overall, 
it is a complicated process that many have tried to elucidate and decipher 15-17?.  
?We do not know what kind of resistant mechanism is working for the resistant cell developed 
herein, but we propose that there are various complex resistant mechanisms at play, just as in 
the clinical setting.  We evaluated whether the combined anti-HER2 Ab and IFN-? therapy 
shows an antitumor effect in vitro, utilizing the resistant cell line to test whether the combined 
therapy has a direct effect on malignant cells without effects from immune cells.
?The lack of antitumor effects with the anti-HER2 Ab therapy alone proved that the cancer 
cells had acquired resistance to Ab therapy.  Combination therapy with IFN-? also significantly 
inhibited cell proliferation, indicating that the combined therapy has a direct effect on cancer 
cells by affecting cellular proliferation.  In addition, the cell number was not decreased, which is 
consistent with our previous in vitro experiments 14?.  It thus seems probable that the Ab therapy 
supresses cell proliferation without decreasing the cell number.  
?We previously demonstrated that the combined Ab and IFN-? therapy changes the malignancy 
of cancer cells 14?.  We also showed that this combination therapy acts on P27kip1 in RAJI and 
the antiCD20 Ab, inhibiting cellular proliferation 18?.  Based on these prior results, we thought 
that the combined therapy would have an inhibitory effect on the malignant features of cancer 
cells, in correlation with the problem of therapeutic resistance and cellular proliferation.  No 
studies have discussed the interaction of intracellular signal transduction by EGFR and EGFR2 
with IFNGR and STAT1, although Shi et al 19? proposed that transduction could be at play with 
the antitumor effect of the anti-HER2 Ab therapy.  Specifically, they showed that the activation 
of STAT1 by IFN-?, which is secreted by immune cells, plays an important role to diminish the 
intracellular signal transduction of HER2.
?In this in vitro study, we thought that signal transduction would be diminished by the 
combined Ab and IFN-? therapy against the resistant cell line.
Combination therapy for the resistant strain showed antitumor effects in the mouse Xenograft 
model
?Next, we evaluated whether the combined anti-HER2 Ab and IFN-? therapy showed 
antitumor effects even in an in vivo experiment with constant immunogenicity.  The combined 
therapy significantly inhibited the tumor volume, thus we concluded that the antitumor immunity 
also worked in vivo, and not only the direct action to the cancer cell was shown in vitro.
Combination therapy and CD8T cells ?Cytotoxic T cell?
?There have been many reports linking the invasive ability of cytotoxic T cells to tumor tissue 
and treatment outcomes in many kinds of cancer 20?21?.  Many researchers have reported on the 
role of the tumor infiltrating lymphocytes, with positive correlations shown between CD8T cells 
and the prognosis, while there is a reverse correlation between Th2 and Treg cells and prognosis.
249Anti-Human Epidermal Growth Factor Receptor 2 ?HER2? Antibody  
and Gamma Interferon Combined Therapy
?As in these previous studies, the accumulation of CD8T cells in tumor tissue was significantly 
increased herein in the combined therapy group compared to other groups using the resistant 
cancer cells.
CD8T cells accumulation and MDSCs
?It is well known that tumor cells use various methods to escape from the immune system. 
Immunosuppressive cells, such as regulatory T cell ?Treg? and MDSCs, are very important for 
cancer progression because these cells inhibit CTL, NK-cell, and NKT cells from accumulating in 
the tumor tissue 22?.  
?In the immunostaining of the tumor tissue, accumulation of MDSCs was significantly 
decreased in the combined-therapy group, while Gr-1 showed an inverse correlation with tumor 
size.  This result is consistent with our prior report of secreted cytokines from cancer tissue 
being inhibited by the combination therapy.  Although we could not prove a direct association 
between the increased accumulation of CD8T cells and the decreased accumulation of MDSCs, 
we propose that the combination therapy induced the decreased accumulation of MDSCs and 
that contributed to the increased accumulation of infiltrating CD8T cells.  Nevertheless, CD-8 
expression was not high and we could not find evidence to explain this finding.  
?Tumor-specific T cells, as part of adaptive immunity, present a molecular MHC Class? on 
the cell surface and show a strong antitumor effect, through the entry of cancer antigenic 
peptide and co-stimulation.  HER2 Ab and the stimulation by IFN-? also raises the MHC 
class I expression of APC?s, leading us to speculate that adaptive immunity is promoted by our 
combination therapy.
Conflicting function of IFN-? and PD-L1
?It is known that ADCC ?antibody-dependent cell cytotoxicity? plays an important role in 
the antitumor effect of molecular targeted medicine 23?24?.  NK-cells, macrophages, and some 
neutrophils possess ADCC activity 24?.  In addition, some researchers reported that IFN-? often 
increases the Fc?R expression of NK cells, while Motohashi and Nakayama 25? reported that IFN-? 
from NK-cells reinforces the direct cell-damaging action through NKT cells.  Thus, IFN-? 
generally works to enhance host immunity ; however, when IFN-? is used in monotherapy, tumor 
growth is actually increased in in vivo experiments.  Therefore, IFN-? also has a negative effect 
on host immunity, such as raising the PD-L1 expression of tumors 26?.
?In this study, only IFN-? treatment raised the expression of PD-L1 in the tumor tissue, thus 
the tumor size was larger than with any other treatment.  On the other hand, the PD-L1 
expression of the combination therapy was decreased.  We could not find any previous data 
about this type of effect, but we propose that only double signals from Ab and IFN-? could 
elicit a new phenomenon in the cancer cells.  To this end, Hou et al 27? reported an association 
between the CD8T cells and tumor tissue of a patient with breast cancer and between the 
expression of PD-L1 and outcome.
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Combination therapy and NKT cells
?Recently, some researchers reported the contribution of NKT cells to antitumor immunity.  For 
example, Motohashi and Nakayama 25? reported on immunotherapy using NKT cells, which also 
play a role in innate immunity, allowing targeting of all cancer cells.  The NKT cells strongly 
activate the above NK-cell and CD8T cells by secreting IFN-?.
?Herein, we did not examine NKT cell accumulation in the tumor tissue ; however, we propose 
that the IFN-? in combination therapy worked as if it was from NKT cells and showed the 
same antitumor effect in this experiment.  In the future, we hope to examine the contribution of 
NKT cells in our combination therapy.
On the clinical application of the combination therapy with IFN-?
?Next, we evaluated which therapy would show the best antitumor effect in vivo, in order 
to determine if this combined therapy could be applied in the clinical setting.  The current 
recommended first-line pharmacotherapy for HER2-positive cancer is chemotherapy with anti-
HER2 Ab 5?7?9?28?.  A similar regimen of chemotherapy is administered for breast cancer 
treatment.   When cancer cells acquire pharmacotherapy resistance, typically within one year, the 
response to therapy halts.
?The median overall survival in the GBG 26 / BIG 3-05 phase ? study of breast cancer is 
24.9 months 29?, while the progression-free survival time in the Toga study of gastric cancer is 6.7 
months, and the median duration of overall survival is 13.8 months.  With such poor prognosis, 
further improvement is urgently required in the clinical setting 5?.
?When progression is found during first line chemotherapy, we have an option to change the 
chemo drug or choose TDM-1, and various RCT are now ongoing regarding the next choice 30?.
?From our prior results, the 7.16.4?DTX therapy showed an antitumor effect equivalent to 
7.16.4? IFN-?, and triple therapy with 7.16.4?DTX? IFN-? showed the highest antitumor 
effect 14?.  Thus, we evaluated the next therapy for cancers that had progressed while on first-
line chemotherapy.  And we tested the immuno-check point inhibitor ?CPI?, which has 
attracted attention recently.  We used the antiPD-L1 Ab for the immuno-check point inhibitor, 
because that showed greater antitumor effect than antiPD-1 Ab in previous experiments.  The 
combination therapy utilizing 7.16.4? IFN-? and DTX or antiPD-L1 Ab treatment also showed 
a high antitumor effect.  CD8T cells did not accumulate in the 7.16.4?DTX? IFN-? therapy, 
while a significantly greater number of CD8T cells accumulated in the 7.16.4? IFN-?? 
antiPD-L1 Ab treatment.
?We proposed that the DTX has a direct cytotoxic effect as well as an antitumor immune 
effect by the host, and that such immunotherapy is more useful for the patient with recurrent 
cancer than chemotherapy.  Typically, the physical condition is poor, due to recent chemotherapy 
use, in addition to the progression of the disease itself.  Accordingly, we showed herein that 
anti-HER2 Ab? IFN-?? CPI showed a significantly higher anti-tumor effect than single-agent 
treatment utilizing CPI alone.
251Anti-Human Epidermal Growth Factor Receptor 2 ?HER2? Antibody  
and Gamma Interferon Combined Therapy
Conclusion
?In this study, we demonstrated an antitumor effect on resistant cancer cells following combined 
anti-HER2 Ab and IFN-? therapy.  The results also suggested that this antitumor effect was 
improved over that achieved with current conventional therapy and that this combination therapy 
would be useful in deciding on the optimal treatment for the many patients who suffer from 
cancer progression due to the development of treatment resistance.
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